Short answer: On October 30, 2026, HHS published a draft policy saying it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. None of the six became FDA-approved. None was added to the official list of substances pharmacies may compound from. It is a promise not to enforce, with conditions, and public comments close on November 13, 2026.
Below is what the policy says, what it does not say, and what it means if you track research peptides.
Where the policy comes from
The notice ran in the Federal Register as FR Doc. 2026-22192 (91 FR 68526), signed by HHS Secretary Robert F. Kennedy, Jr. It is filed under Docket HHS-OASH-2026-0496 on regulations.gov, where the policy text and its appendices are posted.
The notice calls itself a draft. In its own words, the policy "is not binding on HHS or the public." It covers compounding under section 503A of the Food, Drug, and Cosmetic Act. That is the part of the law for pharmacies that fill patient-specific prescriptions, not large outsourcing facilities.
The six peptides and their routes
The policy ties each peptide to one chemical form and to listed routes. Per the policy appendices on the HHS docket:
- BPC-157 (acetate): under the skin, into the muscle, by mouth, and on the skin
- Epitalon (acetate): under the skin or into the muscle, dispensed in intermittent courses
- KPV (acetate): on the skin and by mouth
- MOTS-c (acetate): under the skin or into the muscle
- Semax (free base): in the nose
- TB-500 (acetate): under the skin or into the muscle
A route that is not on the list falls outside the policy.
The conditions a pharmacy has to meet
The non-enforcement promise only applies when every condition holds. The main ones:
- A prescription for a named patient. Section 503A's patient-specific prescription rule still applies.
- One active ingredient. The product may contain a single peptide from the list. Blends of two listed peptides are outside the policy.
- Known identity. The peptide must match the sequence, structure and molecular weight described in the appendix.
- Traceable raw material. The bulk peptide must come from an FDA-registered manufacturer that follows current good manufacturing practice, with a valid certificate of analysis naming where it was made.
- A fixed label line. "This is a compounded drug product. Not for resale."
- Only a cleared syringe. If a delivery device comes with the product, it must be an FDA 510(k)-cleared syringe.
- Reporting. Compounded products, serious adverse events and quality problems go to FDA's MedWatch program and to the states involved.
- Oral forms need data. For anything taken by mouth, the compounder must keep records showing the peptide is adequately absorbed in humans.
What did not change
Three points get lost in the headlines.
They are still not approved drugs. The notice itself says compounded drugs are not FDA-approved, and that FDA does not review their safety, effectiveness or quality before they are sold. Nothing in this policy changes that.
FDA's own drug reviewers disagreed. The policy appendix states that FDA's Center for Drug Evaluation and Research recommended against listing each of the six peptides. The FDA Pharmacy Compounding Advisory Committee voted the other way, and HHS chose to follow the committee. HHS also says it may revisit the policy if a safety signal or product quality issue appears.
The research label still fits. A pharmacy being allowed to compound a peptide says nothing new about what it does in people. Treat anything you read about doses, cycles or effects as research information, not medical advice. Dosing decisions belong with a licensed prescriber.
How long it lasts
The policy is interim. Per the docket text, it runs "until each peptide bulk drug substance is addressed in a final rule." The Federal Register notice adds that FDA's future rulemaking "may propose adding some or all of these peptides" to the 503A bulks list based on the evidence. That rulemaking could add a peptide, leave it off, or narrow its routes. Each step would go through its own notice and comment process.
How to comment before November 13
The notice says written comments are accepted for two weeks after publication. The regulations.gov docket lists the comment period as closing at the end of November 13, 2026, US Eastern time. To comment:
- Open the comment page for the notice.
- Write in plain words. Say who you are (patient, prescriber, pharmacist, researcher) and what you want changed or kept.
- Stick to specifics: a route, a condition, the reporting rule. Specific comments are easier for the agency to act on than general support or opposition.
- Comments are public. Leave out anything you would not want posted under your name.
What this means if you track peptides
If a prescriber writes for one of these six through a compounding pharmacy, the policy's conditions shape what you receive. Expect a single-peptide vial or product, the "compounded drug product" label line, and a route from the list above. A two-peptide blend, an unlisted route, or a product with no traceable pharmacy is outside the policy.
That makes good records more useful, not less. A few things worth writing down every time:
- The pharmacy name, the lot number and the date you received the product
- The strength printed on the label, and how the vial was prepared
- Each dose with the date, time, route and site
- Any side effect, with when it started, so you can report it to your prescriber or to MedWatch
A notebook works. So does an app. A peptide tracker like Dose Track logs each shot with its site and time, keeps vial details with the product, and handles more than one compound side by side, so the record is ready if you or your prescriber need it. If you are comparing options, this roundup of the best peptide tracker apps lays out what each one does. For a longer walk through the policy history, see the Dose Track write-up on the HHS six-peptide compounding policy.
The bottom line
HHS has said it does not intend to take enforcement action against licensed compounders who make BPC-157, Epitalon, KPV, MOTS-c, Semax or TB-500 under strict conditions, while FDA works on formal rules. The peptides are not approved, FDA's drug reviewers recommended against listing them, and the policy is a draft open for comment until November 13, 2026. Read the Federal Register notice and the docket yourself before you rely on a summary, including this one.

